CHG regimen with venetoclax and azacytidine for newly diagnosed acute myeloid leukemia
Tests CHG with venetoclax and azacytidine in adults newly diagnosed with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed acute myeloid leukemia (AML) who have not yet been treated for it.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed AML, diagnosed by the standard World Health Organisation (WHO) criteria.
- Earlier treatment
- People must not have had any earlier treatment for AML.
Main reasons for not taking part
- Active or uncontrolled infection needing systemic treatment within 14 days before enrollment
- Unstable systemic disease, such as severe heart, liver, kidney or metabolic disease needing therapy
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in China
- Navy General HospitalBeijing, ChinaContact: Liren Qian, M.D.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Navy General Hospital, Beijing
- Trial code
- NCT06470841
- Record updated
- 22 August 2024
- Original description
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.Read full original descriptionShow less
CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia
The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.
Inclusion: The patient should, in the investigator's opinion, be able to meet all clinical trial requirements; The patient is willing and able to adhere to the study visit schedule and other protocol requirements; The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO); The patient should not have received any prior treatment for AML.
Exclusion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment; Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy; Pregnant or lactating women.